Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature
| Status: | Completed |
|---|---|
| Conditions: | Endocrine |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 12 - 18 |
| Updated: | 8/9/2018 |
| Start Date: | November 2010 |
| End Date: | September 2016 |
A Randomized Controlled Trial Of The Use Of Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature
When treating very short children in puberty we are time-limited, as sex hormones cause the
growth plates to fuse and growth to end. Growth Hormone (GH), plus drugs that stop puberty,
increase height potential, but leave children sexually infantile at a critical time in
development. Human and animal data show that estrogen, in females and males, is a principal
regulator of the fusion of the growth plate in puberty. Using aromatase inhibitors (AIs),
which block testosterone to estrogen conversion, in boys with different growth disorders, we
have shown that AIs may have beneficial effects enhancing height potential in growth-retarded
males, without affecting their puberty. However, no direct comparison of the effect of AIs
alone vs. conventional GH treatment has been done to date. This study will assess the effect
of AIs alone, GH alone and combination treatment in enhancing height potential in adolescent
boys with idiopathic short stature.
growth plates to fuse and growth to end. Growth Hormone (GH), plus drugs that stop puberty,
increase height potential, but leave children sexually infantile at a critical time in
development. Human and animal data show that estrogen, in females and males, is a principal
regulator of the fusion of the growth plate in puberty. Using aromatase inhibitors (AIs),
which block testosterone to estrogen conversion, in boys with different growth disorders, we
have shown that AIs may have beneficial effects enhancing height potential in growth-retarded
males, without affecting their puberty. However, no direct comparison of the effect of AIs
alone vs. conventional GH treatment has been done to date. This study will assess the effect
of AIs alone, GH alone and combination treatment in enhancing height potential in adolescent
boys with idiopathic short stature.
Inclusion Criteria:
- Males: Ages: 12 - less than 18 years.
- Bone age less than 14 ½ years at study initiation.
- Presence of puberty.
- Idiopathic short stature will be defined as a short child equal or less than -2SD for
height, with normal GH responses to stimuli (> or = 5ng/ml to at least 2
secretagogues) or a normal IGF-I and BP-3, normal body proportions and no other
identifiable growth pathology.
- Accurate growth data for at least 6 months at baseline is available.
Exclusion Criteria:
- Chronic illnesses.
- Chronic use of glucocorticosteroids.
- Previous use of hormonal treatment with AIs, sex steroids or GH in the preceding 6
months.
- Birth weight small for gestational age (SGA).
We found this trial at
4
sites
Nemours Children's Clinic At Nemours Children’s Clinic, Jacksonville, we've treated every child as we would...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials